No conviction changes recorded
Fair Value Distribution — percentile bands
0.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
24.8%/yr
±6.1% · revenue growth to justify current price
FCF-Based Reverse DCF
21.4%/yr
±3.5% · FCF growth to justify current price
THE GAP
Market pricing margin expansion or capex normalization
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
$823M backlog provides 6+ quarters of revenue visibility — the orders are there, it's execution that's lagging. Losses improved 21% YoY, and the trusted/classified computing moat remains intact. If management delivers even modest revenue acceleration with the existing backlog, re-rating from $28 to $35-40 is straightforward.
Turnaround is all talk, no proof. Gross margins compressed to 26% despite restructuring and a 28% R&D cut — that's cutting the seed corn. $938M in goodwill (64% of equity) is an impairment bomb if execution doesn't accelerate. No forward guidance suggests management has low confidence in near-term momentum.
Goodwill impairment, revenue growth below 5% for two consecutive quarters, debt covenant breach
Updated Mar 11
Operationally stabilizing (losses down 21% YoY) but turnaround unproven. $823.5M RPO strong, but 4.4% Q2 revenue growth minimal and margin compression continues. Deeply unprofitable with 2-3 year runw...